Drug Discovery Market Research Reports & Industry Analysis

Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.

Understanding the Drug Discovery Market

  • Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
  • We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
  • We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.

Informed Insights: Your Path to Success

Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.

...Show More ...Show Less


Drug Discovery Industry Research & Market Reports

  • Danicopan Emerging Drug Insight and Market Forecast − 2032

    ... detailed picture of the danicopan for PNH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More

  • ZANAFLEX Drug Insight and Market Forecast − 2032

    ... for spasticity in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a ... Read More

  • EO 2401 Emerging Drug Insight and Market Forecast − 2032

    ... markets. A detailed picture of the EO 2401 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 ... Read More

  • TAFINLAR + MEKINIST Drug Insight and Market Forecast − 2032

    ... major markets. A detailed picture of the TAFINLAR + MEKINIST for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period ... Read More

  • DCVax-L Emerging Drug Insight and Market Forecast − 2032

    ... picture of the DCVax-L for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this ... Read More

  • GYM-329 Emerging Drug Insight and Market Forecast − 2032

    ... detailed picture of the GYM-329 for FSHD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More

  • AKL4 Emerging Drug Insight and Market Forecast − 2032

    ... the AKL4 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More

  • Sprifermin Emerging Drug Insight and Market Forecast − 2032

    ... the sprifermin for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More

  • GABLOFEN Drug Insight and Market Forecast − 2032

    ... for spasticity in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a ... Read More

  • JAKAFI Emerging Drug Insight and Market Forecast − 2032

    ... detailed picture of the JAKAFI for bronchiolitis obliterans syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is ... Read More

  • MPH966 Emerging Drug Insight and Market Forecast − 2032

    ... detailed picture of the MPH966 for bronchiolitis obliterans syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is ... Read More

  • AV-GBM-1 Emerging Drug Insight and Market Forecast − 2032

    ... picture of the AV-GBM-1 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this ... Read More

  • Esophageal Squamous Cell Carcinoma Market Research Report Forecast till 2030

    ... research exercises and item endorsements, and rising public mindfulness are driving market development. The rising commonness of achalasia help market development because achalasia patients have a higher gamble of Esophageal Squamous Cell Carcinoma than everybody. ... Read More

  • TCR-Therapy - Pipeline Insight, 2023

    ... nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage TCR-Therapy Understanding ... Read More

  • Global Eosinophilic Esophagitis (EoE) Treatment Market - 2023-2030

    ... during the forecast period 2023-2030. Eosinophilic esophagitis (EoE) is a chronic allergic or immune disorder of the digestive system in which large numbers of white blood cells called eosinophils are present in the esophagus. It ... Read More

  • HER2-Positive Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2032

    ... and drug resistance mechanisms. In 2022, the United States accounted for the maximum share of the total market of HER2-positive breast cancer in the 7MM was around 60%. The approval of HERCEPTIN marked a turning ... Read More

  • RTX-GRT7039 Emerging Drug Insight and Market Forecast − 2032

    ... the RTX-GRT7039 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More

  • AVASTIN Drug Insight and Market Forecast − 2032

    ... the AVASTIN for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along ... Read More

  • ZULRESSO Drug Insight and Market Forecast − 2032

    ... ZULRESSO for PPD in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the ZULRESSO for PPD. The report provides insights about mechanism of ... Read More

  • LAM561 Emerging Drug Insight and Market Forecast − 2032

    ... picture of the LAM561 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this ... Read More

  • Losmapimod Emerging Drug Insight and Market Forecast − 2032

    ... detailed picture of the losmapimod for FSHD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More

  • JOYCLU Drug Insight and Market Forecast − 2032

    ... for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in this report ... Read More

  • XP-3924 Emerging Drug Insight and Market Forecast − 2032

    ... detailed picture of the XP-3924 for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 ... Read More

  • IMCY-0098 Emerging Drug Insight and Market Forecast − 2032

    ... detailed picture of the IMCY-0098 for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 ... Read More

  • Hypoparathyroidism - Market Insight, Epidemiology And Market Forecast - 2032

    ... hormone (PTH) in the circulation. The most common cause of hypoparathyroidism is the removal of all four parathyroid glands or postoperative complications of thyroidectomy, leading to insufficient PTH levels in the body. Nonsurgical causes of ... Read More

Research Assistance

Live help

Join Alert Me Now!

Sign Up

Find out more on our blog
Cookie Settings